392 related articles for article (PubMed ID: 22675170)
21. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
[TBL] [Abstract][Full Text] [Related]
22. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Tan J; Yang X; Zhuang L; Jiang X; Chen W; Lee PL; Karuturi RK; Tan PB; Liu ET; Yu Q
Genes Dev; 2007 May; 21(9):1050-63. PubMed ID: 17437993
[TBL] [Abstract][Full Text] [Related]
25. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
26. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
27. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
28. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
30. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
31. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation.
Qi Y; Zhang X; Kang Y; Wu J; Chen J; Li H; Guo Y; Liu B; Shao Z; Zhao X
Mol Biosyst; 2015 Jul; 11(7):1980-6. PubMed ID: 25947258
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
35. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.
Li Z; Wang Y; Qiu J; Li Q; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Yang J; Cheng J
Oncotarget; 2013 Dec; 4(12):2532-49. PubMed ID: 24345883
[TBL] [Abstract][Full Text] [Related]
36. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
37. Microchidia protein 2, MORC2, downregulates the cytoskeleton adapter protein, ArgBP2, via histone methylation in gastric cancer cells.
Tong Y; Li Y; Gu H; Wang C; Liu F; Shao Y; Li J; Cao L; Li F
Biochem Biophys Res Commun; 2015 Nov; 467(4):821-7. PubMed ID: 26476214
[TBL] [Abstract][Full Text] [Related]
38. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
39. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
Seward S; Semaan A; Qazi AM; Gruzdyn OV; Chamala S; Bryant CC; Kumar S; Cameron D; Sethi S; Ali-Fehmi R; Morris R; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Cancer Lett; 2013 Aug; 336(1):53-60. PubMed ID: 23603558
[TBL] [Abstract][Full Text] [Related]
40. Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Gaudichon J; Milano F; Cahu J; DaCosta L; Martens AC; Renoir JM; Sola B
PLoS One; 2014; 9(9):e107009. PubMed ID: 25255316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]